Moderna Inc MRNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Moderna Gets Canada Approval for Updated Covid-19 Vaccine
-
Moderna's spending cuts, pipeline shakeup leave doubts about a rebound, analysts say
-
Moderna's stock slides as it slashes research spending, trims pipeline
-
Moderna's experimental mpox vaccine reduces severity of disease, early study finds
-
Super Micro offers investors a bit of relief after stock's worst month on record
-
5 things you need to know about COVID, flu and RSV vaccines this fall
-
Moderna Gets European Approval for RSV Vaccine
-
Updated COVID-19 vaccines from Pfizer, Moderna approved by FDA
Trading Information
- Previous Close Price
- €56.24
- Day Range
- €55.35–56.42
- 52-Week Range
- €55.35–154.76
- Bid/Ask
- €55.22 / €55.50
- Market Cap
- €21.28 Bil
- Volume/Avg
- 680 / 233
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.59
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 5,600
- Website
- https://www.modernatx.com
Competitors
Valuation
|
Metric
|
MRNA
|
PFE
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 20.96 | 15.29 |
Price/Book Value | 1.95 | 1.85 | 5.39 |
Price/Sales | 4.59 | 2.90 | 4.55 |
Price/Cash Flow | — | 21.18 | 17.30 |
Price/Earnings
MRNA
PFE
JNJ
Financial Strength
|
Metric
|
MRNA
|
PFE
|
JNJ
|
|---|---|---|---|
Quick Ratio | 3.77 | 0.51 | 0.77 |
Current Ratio | 4.09 | 0.86 | 1.07 |
Interest Coverage | −169.39 | −0.88 | 24.45 |
Quick Ratio
MRNA
PFE
JNJ
Profitability
|
Metric
|
MRNA
|
PFE
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | −29.83% | 3.50% | 13.17% |
Return on Equity (Normalized) | −39.97% | 8.28% | 32.42% |
Return on Invested Capital (Normalized) | −38.74% | 5.39% | 20.93% |
Return on Assets
MRNA
PFE
JNJ
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Rcmbcgqt | Tzb | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gdbkdrk | Ckgghfj | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fvgshvw | Fvspqz | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vzjbplkrk | Mkmnbl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Bwpltdgb | Jgq | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kjvbtvd | Hgcj | $29.2 Bil | |||
| Moderna Inc
MRNA
| Kpnbmlcln | Gqlc | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Hkgcmlbgy | Dzdh | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vghdbsg | Zdjbnbl | $13.2 Bil | |||
| Incyte Corp
INCY
| Crxsbqtw | Jqdrvs | $13.0 Bil |
United States